Transcend Capital Advisors LLC Buys New Shares in Verona Pharma PLC American Depositary Share $VRNA

Transcend Capital Advisors LLC bought a new stake in Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 3,035 shares of the company’s stock, valued at approximately $287,000.

A number of other institutional investors have also added to or reduced their stakes in VRNA. GAMMA Investing LLC increased its stake in Verona Pharma PLC American Depositary Share by 14.0% in the first quarter. GAMMA Investing LLC now owns 1,837 shares of the company’s stock valued at $117,000 after acquiring an additional 225 shares during the last quarter. Cambridge Investment Research Advisors Inc. increased its stake in Verona Pharma PLC American Depositary Share by 31.3% in the first quarter. Cambridge Investment Research Advisors Inc. now owns 6,168 shares of the company’s stock valued at $392,000 after acquiring an additional 1,469 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. increased its stake in Verona Pharma PLC American Depositary Share by 366.0% in the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 11,486 shares of the company’s stock valued at $720,000 after acquiring an additional 9,021 shares during the last quarter. Sumitomo Mitsui Trust Group Inc. bought a new position in Verona Pharma PLC American Depositary Share in the first quarter valued at $284,000. Finally, Moody Aldrich Partners LLC increased its stake in Verona Pharma PLC American Depositary Share by 1.7% in the first quarter. Moody Aldrich Partners LLC now owns 96,603 shares of the company’s stock valued at $6,133,000 after acquiring an additional 1,661 shares during the last quarter. Institutional investors own 85.88% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms recently commented on VRNA. TD Cowen cut Verona Pharma PLC American Depositary Share from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, July 9th. Piper Sandler lowered shares of Verona Pharma PLC American Depositary Share from a “strong-buy” rating to a “hold” rating in a report on Thursday, July 10th. Zacks Research raised shares of Verona Pharma PLC American Depositary Share to a “hold” rating in a report on Friday, August 8th. Jefferies Financial Group reiterated a “hold” rating and issued a $107.00 price objective (down previously from $140.00) on shares of Verona Pharma PLC American Depositary Share in a report on Wednesday, July 9th. Finally, Truist Financial downgraded Verona Pharma PLC American Depositary Share from a “strong-buy” rating to a “hold” rating in a report on Wednesday, July 9th. Two investment analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Verona Pharma PLC American Depositary Share presently has a consensus rating of “Hold” and an average target price of $109.00.

Verona Pharma PLC American Depositary Share Price Performance

VRNA opened at $106.91 on Friday. The company has a market cap of $9.21 billion, a P/E ratio of -107.99 and a beta of 0.05. The business’s 50-day moving average price is $106.51 and its 200-day moving average price is $94.01. The company has a current ratio of 10.71, a quick ratio of 10.54 and a debt-to-equity ratio of 0.87. Verona Pharma PLC American Depositary Share has a 12 month low of $31.09 and a 12 month high of $106.93.

Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) last announced its quarterly earnings results on Wednesday, August 6th. The company reported $0.13 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.01) by $0.14. Verona Pharma PLC American Depositary Share had a negative return on equity of 21.12% and a negative net margin of 36.62%.The company had revenue of $103.14 million for the quarter, compared to the consensus estimate of $90.41 million. On average, equities analysts expect that Verona Pharma PLC American Depositary Share will post -1.95 EPS for the current year.

Verona Pharma PLC American Depositary Share Profile

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis.